Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 1 N=34 Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness — 5; 4; 1; 6 Participants
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 1 N=11 Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
HIV INFECTIONS
Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
Phase 2 N=24 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
HIV Infections
Primary: HIV Viral Load — -0.18; -0.05; 0.002; 0.26 HIV RNA copies/mL — p=0.008
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Phase 2 N=68 Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
HIV-1
Primary: Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site — 0 Percentage of participants
N/A N=943 Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
HIV Infection
Primary: Determination of the Prevalence of R5 and X4-tropic Variants of HIV in HIV-infected Population in Russia — 123; 85; 114; 78 participants
Phase 1 N=21 Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
HIV-infection
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Phase 1 N=16 GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Early Phase 1 N=9 Autologous CD4 T-Cells in HIV (C34-CXCR4)
Hiv
Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants
Phase 2 N=92 Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
HIV Infection
Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants
Phase 2 N=160 Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants
Phase 1 N=33 Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
HIV Antibodies
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of N6LS Product Administration Alone or N6LS Co-Administered With rHuPH20 — 3; 1…
Phase 2 N=123 Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Herpes Zoster
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants
Phase 2 N=27 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
HIV Infections
Primary: Anti-Tat Antibody Titer — 698; 4 ng/mL
Phase 1 N=49 Study of Novel Antiretrovirals in Participants With HIV-1
HIV-1-infection
Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 1 N=73 First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
HIV Infections
Primary: Part 1: Number of Participants With Adverse Events (AEs) — 3; 2; 1; 3 Participants
Phase 1 N=16 Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Human Immunodeficiency Virus Prevention · Human Immunodeficiency Virus (HIV)
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants
Phase 2 N=22 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio